Translational Biomedicine©
14 (4) 2023 : 001-002 • Review Article

Staphylococcus aureus and skin infections

Dr. Lindsay Phillips*
Department of Microbiology and micro-organism, University of HK, United Kingdom

AUTHORS' CONTRIBUTION: (A) Study Design · **(B)** Data Collection . **(C)** Statistical Analysis · **(D)** Data Interpretation · **(E)** Manuscript Preparation · **(F)** Literature Search · **(G)** No Fund Collection

ABSTRACT

Staphylococcus aureus, commonly known as "staph," is a type of bacteria that is frequently found on the skin and in the nasal passages of healthy people. While *S. aureus* is usually harmless, it can cause a range of illnesses when it enters the body, from minor skin infections to life-threatening diseases. *S. aureus* can cause a variety of infections, including skin and soft tissue infections, bloodstream infections, pneumonia, and endocarditis. It is a leading cause of hospital-acquired infections and can be particularly dangerous for people with weakened immune systems. Staphylococcus aureus is a gram-positive bacterium that is a common cause of infections in both community and healthcare settings. It is a highly adaptable organism, able to survive and thrive in a variety of environments, including the human body. *S. aureus* infections range from minor skin infections to life-threatening conditions such as sepsis, pneumonia, and endocarditis. *S. aureus* produces a wide range of virulence factors that contribute to its pathogenicity. These include surface proteins that promote adhesion to host cells, toxins that damage host tissues, and enzymes that facilitate the spread of the bacterium. The ability of *S. aureus* to produce these factors is controlled by a complex regulatory network that responds to changes in the environment.

Keywords: *Staphylococcus aureus*; Life-threatening diseases; Pneumonia; Immune systems

Address for correspondence:

Dr. Lindsay Phillips
Department of Microbiology and micro-organism, University of HK, United Kingdom
E-mail: lynbish.ph@gmail.com

Word count: 1261 **Tables:** 00 **Figures:** 00 **References:** 10

Received: 03.07.2023, Manuscript No. ipacm-23-13691; **Editor assigned:** 05.07.2023, PreQC No. P-13691; **Review ed** 19.07.2023, QC No. Q-13691; **Revised** 24.07.2023, Manuscript No. R-13691; **Published:** 29.07.2023

INTRODUCTION

One of the most concerning aspects of *S. aureus* is its ability to develop resistance to antibiotics. Methicillin-resistant *S. aureus* (MRSA) is a strain of *S. aureus* that is resistant to multiple antibiotics and is particularly difficult to treat. MRSA infections can lead to sepsis, pneumonia, and other serious complications [1]. Preventing *S. aureus* infections involves a combination of good hygiene and infection control practices. Hand hygiene is critical in preventing the spread of *S. aureus* and other harmful bacteria [2]. Healthcare providers should follow strict infection control procedures to prevent the transmission of *S. aureus* in healthcare settings. For people who are at higher risk of *S. aureus* infections, such as those with weakened immune systems or who are undergoing medical procedures, prophylactic antibiotics may be used to prevent infections. However, overuse of antibiotics can contribute to the development of antibiotic-resistant strains of bacteria like MRSA, so antibiotics should be used judiciously [3]. Treatment of *S. aureus* infections typically involves antibiotics, but the choice of antibiotic may depend on the severity of the infection and whether or not the bacteria are resistant to certain drugs. In some cases, surgery may be necessary to remove infected tissue or drain abscesses.

One of the most significant challenges posed by *S. aureus* is its ability to develop resistance to antibiotics [4]. Methicillin-resistant *S. aureus* (MRSA) is a strain that has become a major public health concern due to its resistance to multiple classes of antibiotics. The emergence of MRSA has led to the development of alternative treatment strategies, such as the use of antimicrobial peptides and vaccines. *S. aureus* is also a major concern in the food industry, as it can cause foodborne illness [5]. It has been found in a variety of foods, including dairy products, meat, and seafood. The presence of *S. aureus* in food is a particular concern in developing countries, where food safety regulations may be less stringent. Prevention and control of *S. aureus* infections rely on a combination of measures, including good hygiene practices, infection control measures in healthcare settings, and appropriate use of antibiotics. In addition, the development of new treatment strategies, such as vaccines and novel antimicrobial agents, is critical in the fight against this pathogen [6].

SKIN INFECTIONS HUMANS AND ANIMALS

Staphylococcus aureus, commonly referred to as "Staph," is a gram-positive bacterium that is often found on the skin and in the nasal passages of humans and animals. It is a member of the Staphylococcus genus, which includes

several other species of bacteria, many of which are also found on the skin and in mucous membranes [7]. *S. aureus* is a facultative anaerobe, meaning that it can grow both in the presence and absence of oxygen, and is known for its ability to cause a wide range of infections, from minor skin infections to life-threatening diseases. One of the distinguishing characteristics of *S. aureus* is its ability to produce a variety of virulence factors, including toxins and enzymes that allow it to evade the host's immune system and cause disease. Some of these factors include coagulase, which causes the bacterium to clot blood, and the exotoxins, which can cause a range of symptoms such as fever, nausea, vomiting, and even shock. *S. aureus* infections can be acquired through a variety of means, including direct contact with infected individuals, contaminated objects, or even through exposure to the bacteria in the environment [8]. While the majority of *S. aureus* infections are mild and can be treated with antibiotics, the bacterium has developed resistance to many commonly used antibiotics, which can make infections more difficult to treat. In recent years, the emergence of methicillin-resistant *S. aureus* (MRSA) has become a major public health concern. MRSA is a strain of *S. aureus* that is resistant to multiple antibiotics, including methicillin, which is commonly used to treat bacterial infections. This can make infections caused by MRSA more difficult to treat and can lead to more severe outcomes [9]. Staphylococcus aureus is a Gram-positive bacterium that is commonly found on the skin and in the nasal cavity of humans. While it is typically harmless in healthy individuals, it can cause a wide range of infections in those with weakened immune systems or who have undergone medical procedures. Over the years, *S. aureus* has become a major public health concern due to the increasing prevalence of antibiotic resistance. Methicillin-resistant *S. aureus* (MRSA) in particular has become a significant problem in healthcare settings, as it can cause serious and difficult-to-treat infections. Additionally, community-acquired MRSA has emerged as a major threat, with outbreaks occurring in schools, sports teams, and other close-contact settings. The ability of *S. aureus* to produce a range of virulence factors, including toxins, enzymes, and adhesins, contributes to its ability to cause disease [10]. It is also capable of forming biofilms, which can protect the bacteria from the host immune system and antibiotics. Preventing and controlling *S. aureus* infections requires a multifaceted approach. This includes proper hygiene practices, such as hand washing and cleaning of surfaces, as well as appropriate use of antibiotics to reduce the development of resistance. Vaccines are also being developed to target *S. aureus* infections, although these have had limited success so far.

CONCLUSION

While *S. aureus* is a common bacterium that is usually harmless, it can cause serious infections that are difficult to treat, particularly if the bacteria are resistant to antibiotics. Good hygiene practices and infection control measures are critical in preventing the spread of S. aureus, and antibiotics should be used judiciously to help prevent the development of antibiotic-resistant strains. If you have concerns about *S. aureus* infections, speak with your healthcare provider. *S. aureus* is a versatile and dangerous pathogen that poses a significant threat to human health. The emergence of antibiotic-resistant strains and its ability to cause foodborne illness make it a major public health concern. Effective prevention and control measures, as well as the development of new treatment strategies, are essential in the ongoing battle against this pathogen.

S. aureus is an important bacterium that has significant implications for human health. While it is a normal part of the human microbiota, under certain conditions, it can cause a wide range of infections and has developed resistance to many commonly used antibiotics, making it a significant challenge for healthcare professionals and researchers alike.

S. aureus is a versatile and opportunistic pathogen that can cause a wide range of infections in humans. With the increasing prevalence of antibiotic resistance, it is crucial that we continue to develop new treatments and prevention strategies to combat this pathogen. Further research is needed to better understand the mechanisms of virulence and resistance in *S. aureus*, and to identify new targets for drug development.

REFERENCES

1. **Stevenson TH, Castillo A, Lucia LM, et al.** Growth of Helicobacter pylori in various liquid and plating media. *Lett Appl Microbiol.* 2000;30: 192-6.
2. **Johnson RC, Harris VG**. Differentiation of Pathogenic and Saprophytic Leptospires I Growth at Low Temperatures. *J Bacteriol.* 1967;94: 27-31.
3. **Jugder BE, Watnick PI**. Vibrio cholerae Sheds Its Coat to Make Itself Comfortable in the Gut. *Cell Host & Microbe.* 2020;27: 161-163.
4. **Lawrence CM, Menon S, Eilers BJ, et al.** Structural and functional studies of archaeal viruses. *J Biol Chem* 2009;284: 12599-603.
5. **Cook S, Moureau G, Harbach RE, et al.** Isolation of a novel species of flavivirus and a new strain of Culex flavivirus from a natural mosquito population in Uganda. *J Gen Virol.* 2009;90: 2669-78.
6. **Barré-Sinoussi F, Chermann JC, Nugeyre MT, et al**. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science.*1983;220: 868-71.
7. **D'Herelle F**. on an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr F D'Herelle, presented, Mr Roux. *Res Microbiol.*2007;158: 553-54.
8. **Foucher J, Chanteloup E, Vergniol J, et al.** Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. *Gut.* 2006;55: 403-408.
9. **Saiman L.** Microbiology of early CF lung disease. *Paediatr Respir Rev*. 2004;5:367-9.
10. **Rudkin JK, McLoughlin RM, et al.** Bacterial toxins: Offensive, defensive, or something else altogether. *PLOS Pathogens*. 2017;13:1006452.